#ESMO23 Aftimos presents final analysis of TULIP evaluating trastuzumab duocarmazine for HER2+ MBC. PFS benefit maintained. No OS benefit. High risk keratitis and some ILD. Doesn't seem that it can compete. @OncoAlert

Jivadco (trastuzumab duocarmazine) - Byondis, Medac

Oct 22, 2023